|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5580 EUR | -2.11% |
|
-13.49% | -63.67% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 52.03M | |
| 2.69% | 2.76% | 64.28x | 6.03x | 5.2x | 19.32x | 25.87x | 312B | |
| 1.74% | 1.81% | 22.78x | 1.9x | 3.13x | 11.19x | 18.46x | 66.59B | |
| 2.59% | 2.76% | 17.2x | 1.49x | 2.19x | 7.51x | 8.98x | 8.53B | |
| -.--% | -.--% | 20.7x | 5.51x | 5.85x | 16.54x | 17.29x | 4.1B | |
| 0.8% | 0.81% | 38.22x | 2.3x | 2.19x | 27.44x | 40.93x | 3.51B | |
| -.--% | -.--% | 107.57x | - | - | - | - | 2.78B | |
| 4.05% | 3.5% | 17.45x | 0.76x | 1.37x | 24.54x | 42.01x | 1.07B | |
| Average | 1.7% | 1.66% | 41.17x | 3.00x | 3.32x | 17.76x | 25.59x | 49.81B | |
| Weighted average by Cap. | 2.47% | 2.54% | 55.83x | 5.18x | 4.75x | 17.76x | 24.34x |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
